Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma

  • Barajas R
  • Pampaloni M
  • Clarke J
  • et al.
N/ACitations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.

Cite

CITATION STYLE

APA

Barajas, R. F., Pampaloni, M. H., Clarke, J. L., Seo, Y., Savic, D., Hawkins, R. A., … Cha, S. (2015). Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Reports in Radiology, 2015, 1–4. https://doi.org/10.1155/2015/731361

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free